Bruker (NASDAQ:BRKR) Stock Passes Above 200 Day Moving Average – Here’s Why

Bruker Corporation (NASDAQ:BRKR) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $44.59 and traded as high as $61.21. Bruker shares last traded at $59.71, with a volume of 1,988,242 shares changing hands.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup lifted their price target on shares of Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Guggenheim increased their price objective on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday. JPMorgan Chase & Co. boosted their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus price target of $54.54.

Bruker Stock Up 0.8%

The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. The firm has a market cap of $9.23 billion, a P/E ratio of -252.67, a price-to-earnings-growth ratio of 1.91 and a beta of 1.31. The stock’s fifty day moving average is $49.30 and its two-hundred day moving average is $44.68.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm’s revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio is presently -83.33%.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

Large investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC purchased a new position in shares of Bruker in the fourth quarter worth $26,000. Allworth Financial LP grew its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the period. Essential Partners LLC bought a new stake in shares of Bruker during the 1st quarter valued at $36,000. Parallel Advisors LLC grew its position in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the period. Finally, Summit Securities Group LLC bought a new position in shares of Bruker in the 4th quarter worth about $50,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.